Next Article in Journal
Previous Article in Journal

Crystals 2012, 2(3), 1248-1252; doi:10.3390/cryst2031248

Short Note
One-Pot Synthesis and Crystal Structure of Methyl 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylate
Aamer Saeed 1,*, Ifzan Arshad 1 and Ulrich Flörke 2
Department of Chemistry, Quaid-I-Azam University, Islamabad 45320, Pakistan; Email:
Department of Inorganic and Analytical Chemistry, Universität Paderborn, Warburgerstr. 100, D-33098, Paderborn, Germany; Email:
Author to whom correspondence should be addressed; Email:; Tel.: +92-51-9064-2128; Fax: +92-51-9064-2241.
Received: 15 May 2012; in revised form: 31 July 2012 / Accepted: 14 August 2012 /
Published: 27 August 2012


: The title compound, Methyl 5-Hydroxy-1-Phenyl-1H-Pyrazole-3-Carboxylate (C11H10N2O3), was prepared by a one-pot, two-component reaction of an equimolar mixture of phenyl hydrazine and dimethyl acetylene dicarboxylate (DMAD) at reflux temperature for 2 h in a mixture of toluene and dichloromethane as solvent. C11H10N2O3 was crystallized from an ethanol solution in monoclinic space group P21/c with unit cell dimensions a = 9.5408(16), b = 9.5827(16), c = 11.580(2) Å, β = 105.838(3)°, V = 1018.5(3) Å3, Z = 4.
pyrazole; methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate; crystal structure

1. Introduction

Over the years, pyrazoles have enjoyed a prominent place in heterocyclic chemistry largely due to the wide range of biological activity demonstrated by this class of compounds for uses such as pharmaceuticals and agricultural and veterinary drugs [1,2,3]. They possess anti-obesity [4], antianxiety [5] and HIV-1 reverse transcriptase inhibitor [6], anti-hyperglycemic, anti-pyretic, analgesic, anti-inflammatory and hypoglycemic activity [7,8]. Their derivatives are used as important intermediates in the preparation of drug molecules, as well as in the laboratory synthesis of natural products. The presence of ester functionality in pyrazoles further offers an attractive method for the generation of derivatives which may possess interesting medicinal and biological properties.

In this paper, we describe a new one pot synthesis and structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1a) which is a tautomeric form of methyl 5-oxo-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylate (1b) (Figure 1). The tautomeric form 1a is predominant in a DMSO-d6 solution and this form also crystallizes from ethanol solution.

The structure of the tautomer 1b is found in the Cambridge database and is an organocatalyst for organic reactions [9].

Crystals 02 01248 g001 1024
Figure 1. Tautomeric forms of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate.

Click here to enlarge figure

Figure 1. Tautomeric forms of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate.
Crystals 02 01248 g001 1024

2. Results and Discussion

Methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1) was prepared by refluxing a 1:1 molar ratio of phenyl hydrazine (2) and dimethylacetylene dicarboxylate (3) for 2 h, in a mixture of toluene and dichloromethane used as a solvent (Figure 2).

Crystals 02 01248 g002 1024
Figure 2. Synthesis of title compound 1.

Click here to enlarge figure

Figure 2. Synthesis of title compound 1.
Crystals 02 01248 g002 1024

The structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate was confirmed by 1H NMR spectra which revealed the presence of a singlet at δ 5.98 ppm assignable to 4-pyrazole H. Another singlet in the 1H NMR at δ 3.80 ppm is assigned to three protons of ester methoxy group. A singlet for hydroxyl proton appeared at δ 12.16 ppm. The FTIR showed peaks at 3204 cm−1 for OH stretching vibrations, and at 1728 cm−1 for the ester carbonyl in addition to other characteristic peaks.

Single crystals suitable for X-ray diffraction were obtained by recrystallization from ethanol. The molecular structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate is depicted in Figure 3.

The phenyl and the pyrazole ring planes are inclined at a dihedral angle dihedral angle of 60.83(5)°, the carboxylate group lies in the pyrazole plane with a C8-C9-C10-O2 torsion angle of 173.0(1)°. There are no unexpected geometric parameters. A closely related molecular structure 3-ethoxycarbonyl-1-phenyl-1H-pyrazol-5-yl 4-chlorobenzoate is known [10] with a 4-chlorobenzoate group replacing the –OH. Crystal packing shows strong O1–H…N2 (x, −y + 0.5, z + 0.5) interactions with H…N2 1.95 Å and O–H...N 167.9° that link the molecules into chains along the c axis. Weaker C2–H…O3 (−x + 2, −y + 1, −z) hydrogen bonds with H…O 2.42 Å and C–H…O 156.3° then connect these chains into centrosymemtric dimers (Figure 4).

Crystals 02 01248 g003 1024
Figure 3. The molecular structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1). Anisotropic displacement ellipsoids are drawn at the 50% probability level.

Click here to enlarge figure

Figure 3. The molecular structure of methyl 5-hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1). Anisotropic displacement ellipsoids are drawn at the 50% probability level.
Crystals 02 01248 g003 1024
Crystals 02 01248 g004 1024
Figure 4. Crystal packing of 1 viewed along the b-axis with hydrogen bonding pattern shown as dashed lines. H atoms not involved in bonding are omitted.

Click here to enlarge figure

Figure 4. Crystal packing of 1 viewed along the b-axis with hydrogen bonding pattern shown as dashed lines. H atoms not involved in bonding are omitted.
Crystals 02 01248 g004 1024

3. Experimental Section

3.1. General

The melting point was determined on a Stuart SMP3 melting point apparatus and is uncorrected. FT IR spectra were recorded using a Shimadzu IR 460 spectrophotometer by the Attenuated Total Reflectance (ATR) method. 1H NMR spectrum was determined as DMSO-d6 solution at 300 MHz using a Bruker AM-300 spectrophotometer. Mass Spectra (EI, 70 eV) were recorded on a GC-MS instrument and the elemental analysis was conducted using a LECO-183 CHNS analyzer.

3.2. Synthesis of Methyl 5-Hydroxy-1-phenyl-1H-pyrazole-3-carboxylate (1)

The title compound, C11H10N2O3, was prepared by stirring at reflux a mixture of phenyl hydrazine (0.22 g, 2 mmol) (2) and dimethylacetylene dicarboxylate (DMAD) (0.28 g, 2 mmol) (3) for 2 h in a 10 mL (1:1) mixture of toluene and DCM. The completion of reaction was monitored by thin layer chromatography. After completion the solvent was evaporated under reduced pressure and the white solid obtained were recrystallized from ethanol. m.p 188 °C. 1H NMR (300 MHz, DMSO-d6) δ 3.80 (3H, s), 5.98 (1H, s), 7.34–7.74 (5H, m), 12.16 (1H, s); FTIR (ATR): 3204, 1728, 1249 cm−1. Anal calcd. for C11H10N2O3: C, 60.55; H, 4.62; N, 12.84%; Found C, 60.49; H, 4.67; N, 12.78%.

3.3. X-ray Structure Determination

C11H10N2O3, Mr = 218.2, crystal size 0.21 × 0.39 × 0.40 mm3, monoclinic, space group P21/c, a = 9.5408(16), b = 9.5827(16), c = 11.580(2) Å, b = 105.838(3)°, V = 1018.5(3) ų, Z = 4, ρcalc = 1.423 mg/cm3, μ = 0.106 mm1, F(000) = 456. Data were collected at 130(2) K on a Bruker [11] AXS SMART APEX CCD diffractometer using MoKα radiation; 7713 reflections collected 2.22 < Θ < 27.88°.

The structure was solved by direct methods [12], and refined on F2 by full-matrix least-squares [12] with 147 parameters and 2402 unique intensities (Rint = 0.034). All non-hydrogen atoms were refined anisotropically. All H atom positions were clearly derived from difference Fourier maps and the refined on idealized positions with Uiso = 1.2 Ueq (C/O) or 1.5Ueq (Cmethyl, O), C–H distances of 0.95–0.98 Å and O–H 0.84 Å. The methyl H atoms were allowed to rotate but not to tip. CCDC-879881.

4. Conclusions

A highly efficient synthesis of compound 1 was carried out under mild conditions. The structure assignment as the methyl 5-hydroxy-1-phenyl-1H-3pyrazole-3-carboxylate tautomer was supported by 1H NMR data, elementary analysis and the crystallographic studies.


  1. Noga, E.J.; Barthalmus, G.T.; Mitchell, M.K. Cyclic amines are selective cytotoxic agents for pigmented cells. Cell Biol. Int. 1986, 10, 239–247. [Google Scholar] [CrossRef]
  2. Subas, M.S.; Kristin, M.L.D.; Martha, L.M.; Bryson, R.; Andrei, S.; Robert, J.R.; David, A.K.; Hengmiao, C.; Jin, L.; Burton, H.J.; et al. 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part 1: Structure–Activity relationship studies of 5-alkylamino pyrazoles and discovery of a potent, selective, and orally active analog. Bioorg. Med. Chem. Lett. 2006, 16, 288–292. [Google Scholar]
  3. Katritzky, A.R.; Wang, M.; Zhang, S.; Voronkov, M.V. Regioselective synthesis of polysubstituted pyrazoles and isoxazoles. J. Org. Chem. 2001, 66, 6787–6791. [Google Scholar]
  4. Serena, T. Rimonabant: A cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutr. Metab. Cardiovasc. Dis. 2006, 16, 156–162. [Google Scholar] [CrossRef]
  5. David, J.W.; Thomas, C.; Ronald, R.; James, A.K.; Hyacinth, A.; Duff, D.; Robert, M.; Thomas, A.P.; Kim, T.Z.; Thomas, G.H.; Lawrence, D.W. Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2067–2070. [Google Scholar]
  6. Genin, M.J.; Biles, C.; Keiser, B.J.; Poppe, S.M.; Swaney, S.M.; Tarpley, W.G.; Romero, D.L. Novel 1,5-diphenylpyrazole non nucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: Lead identification and SAR of 3- and 4-substituted derivatives. J. Med. Chem. 2000, 43, 1034–1040. [Google Scholar] [CrossRef]
  7. Cottineau, P.; Toto, C.; Marot, A.; Pipaud, J.C. Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids. Bioorg. Med. Chem. Lett. 2002, 12, 2105–2108. [Google Scholar]
  8. Lee, K.Y.; Kim, J.M. Regioselective synthesis of 1,3,4,5-tetrasubstituted pyrazoles from Baylis–Hillman adducts. Tetrahedron Lett. 2003, 44, 6737–6740. [Google Scholar] [CrossRef]
  9. Tzeng, Z.H.; Yang, S.W.; Liu, P.M.; Chen, K.M. Optical resolution of 5-Oxo-1-phenyl-pyrazolidine-3-carboxylic acid as a new organocatalyst for organic reactions. J. Chin. Chem. Soc. (Taipei) 2008, 55, 626–631. [Google Scholar]
  10. Zheng, P.W.; Fan, M.L.; Duan, X.M.; Li, J.S.; Huang, P.M. 3-Ethoxycarbonyl-1-phenyl-1H-pyrazol-5-yl 4-chlorobenzoate. Acta Cryst. 2006, E62, o311–o312. [Google Scholar]
  11. Bruker AXS Inc. SMART (Version 5.63),SAINT (Version 6.02); Bruker AXS Inc.: Madison, WI, USA, 2002.
  12. Sheldrick, G.M. A short history of SHELX. Acta Cryst. 2008, A64, 112–122. [Google Scholar]
Crystals EISSN 2073-4352 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert